Core Viewpoint - Hainan Huayan Collagen Technology Co., Ltd. has made significant strides in its global expansion by partnering with Thai Wan Sheng Group to invest in a marine collagen peptide factory in Thailand, emphasizing its commitment to independent innovation in the biopetide industry [2] Group 1: Company Overview and Innovations - Hainan Huayan is recognized as a national high-tech enterprise focusing on the biopetide industry, aiming to break through technological barriers and achieve deep integration of technology and industry [2][3] - The company has developed a range of innovative products, including the first domestic collagen tripeptide and elastic protein peptide, and has filed nearly 200 patents [6][9] - The firm has established a dual-wheel model of "raw materials + customization" to cater to different market demands, ensuring a strong connection between technology and market needs [9] Group 2: Challenges and Responses - The company faced significant early challenges, including reliance on imported equipment and strict patent barriers, which fueled its determination for independent research and development [3][4] - After two years of research, the company successfully localized fish collagen peptide production in 2007, marking a critical technological breakthrough [4] - The team has developed a mass production technology for cyclic collagen peptides, overcoming the absence of mature international processes [4] Group 3: Strategic Vision and Market Positioning - Hainan Huayan aims to lead the global biopetide market by pushing for high-purity, high-activity products with clinical evidence, while also participating in international standard-setting [10] - The company is expanding its production bases in multiple regions, including Hainan, Henan, Shandong, and Thailand, with products exported to over 50 countries [9][10] - Future strategies include capacity expansion, technological iteration, and brand building, focusing on enzyme engineering and high-value utilization of marine by-products [10][11]
财经聚焦·对话企业掌门人丨鱼鳞变“黄金”,“中国肽”如何冲破技术藩篱?——对话海南华研胶原科技股份有限公司董事长郭红星
Xin Hua Wang·2025-12-10 11:39